Cenerimod in severe renal impairment

Phase 1, open-label trial of cenerimod (2 arms), sponsored by Viatris. Primary endpoints: Area under the plasma concentration-time curve from time zero to time t of the last measured concentration above the limit of quantification at 52 days, Area under the plasma concentration-time curve from 0 to infinity at 52 days and 6 more. Started Sep 2021; status: completed.